| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0014-5793(94)00773-X |
| P698 | PubMed publication ID | 8070571 |
| P2093 | author name string | D Caput | |
| D Shire | |||
| B Calandra | |||
| M Rinaldi-Carmona | |||
| S Martinez | |||
| C Congy | |||
| F Barth | |||
| J Maruani | |||
| G Néliat | |||
| M Héaulme | |||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CNR2 | Q17907844 |
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| P304 | page(s) | 240-244 | |
| P577 | publication date | 1994-08-01 | |
| P1433 | published in | FEBS Letters | Q1388051 |
| P1476 | title | SR141716A, a potent and selective antagonist of the brain cannabinoid receptor | |
| P478 | volume | 350 |
| Q34472174 | 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. |
| Q42556563 | (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase |
| Q34946743 | (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs. |
| Q44392551 | (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. |
| Q78181698 | 3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands |
| Q34232856 | 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism |
| Q42372012 | 5-(4-Chloro-phen-yl)-1-(2,4-dichloro-phen-yl)-4-methyl-N-(3-pyridylmeth-yl)-1H-pyrazole-3-carboxamide |
| Q42836455 | A Method for Parallel Solid-Phase Synthesis of Iodinated Analogs of the Cannabinoid Receptor Type I (CB1) Inverse Agonist Rimonabant |
| Q43759232 | A cannabinoid mechanism in relapse to cocaine seeking. |
| Q44057993 | A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition |
| Q39888165 | A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis |
| Q44345700 | A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation |
| Q33839407 | A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy |
| Q34094132 | A role for the endogenous cannabinoid system in the peripheral control of pain initiation |
| Q44567295 | A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart |
| Q34482035 | AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice |
| Q24647198 | AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors |
| Q28270589 | AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies |
| Q48797804 | AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain |
| Q46220923 | AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain |
| Q47426349 | Acetaminophen Relieves Inflammatory Pain through CB1 Cannabinoid Receptors in the Rostral Ventromedial Medulla. |
| Q48567366 | Action of delta-9-tetrahydrocannabinol on GABA(A) receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice |
| Q46619355 | Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. |
| Q38867935 | Activation of LVGCCs and CB1 receptors required for destabilization of reactivated contextual fear memories |
| Q45022904 | Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation |
| Q28270721 | Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1 |
| Q45108255 | Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock |
| Q42625887 | Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis |
| Q73575705 | Activational role of cannabinoids on movement |
| Q44176753 | Acute or chronic effects of cannabinoids on spontaneous or pharmacologically induced yawning in rats |
| Q46097005 | Addiction medicine perspective on the medicalization of marijuana |
| Q40928922 | Addiction: brain mechanisms and their treatment implications |
| Q45079498 | Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. |
| Q34410764 | Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations. |
| Q41760767 | Altered Mesolimbic Dopamine System in THC Dependence |
| Q28235579 | An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing |
| Q28284331 | An analgesia circuit activated by cannabinoids |
| Q33861944 | An investigation into the structural determinants of cannabinoid receptor ligand efficacy |
| Q28185158 | An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors |
| Q24650317 | Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity |
| Q40922925 | Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors |
| Q24673420 | Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats |
| Q36155353 | Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors |
| Q48272826 | Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. |
| Q33828435 | Anandamide capacitates bull spermatozoa through CB1 and TRPV1 activation |
| Q40032518 | Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. |
| Q40612911 | Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells |
| Q46008136 | Anandamide injected into the lateral ventricle of the brain inhibits submandibular salivary secretion by attenuating parasympathetic neurotransmission. |
| Q48983880 | Anandamide modulates the expression of GnRH-II and GnRHRs in frog, Rana esculenta, diencephalon |
| Q39652985 | Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro |
| Q51185952 | Anandamide regulates the expression of GnRH1, GnRH2, and GnRH-Rs in frog testis. |
| Q45096367 | Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. |
| Q46819535 | Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats |
| Q37029517 | Antagonist-elicited cannabis withdrawal in humans |
| Q35847290 | Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice |
| Q36076549 | Anti-hyperlipidemic effect of soybean extract fermented by Bacillus subtilis MORI in db/db mice |
| Q48704602 | Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. |
| Q92130949 | Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice |
| Q41351855 | Antiaversive effects of cannabinoids: is the periaqueductal gray involved? |
| Q33953174 | Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. |
| Q46713327 | Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions |
| Q44318882 | Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice |
| Q47282573 | Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. |
| Q44551668 | Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors |
| Q33901801 | Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents? |
| Q51727895 | Assay of CB1 Receptor Binding. |
| Q43846366 | Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects |
| Q47897399 | Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. |
| Q34280204 | BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. |
| Q28551268 | Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats |
| Q39417079 | Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054. |
| Q44574410 | Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover |
| Q42154370 | Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. |
| Q35028253 | Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol |
| Q40873810 | Behaviroal, pharmacological, and molecular characterization of an amphibian cannabinoid receptor |
| Q59054886 | Bidirectional control of airway responsiveness by endogenous cannabinoids |
| Q42547084 | Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors |
| Q49096545 | Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors |
| Q46425016 | Biosynthesis and purification of a hydrophobic peptide from transmembrane domains of G-protein-coupled CB2 receptor |
| Q37360643 | Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance |
| Q44705389 | Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior |
| Q44046073 | Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. |
| Q48189119 | Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function |
| Q41781544 | Brain RVD-haemopressin, a haemoglobin-derived peptide, inhibits bombesin-induced central activation of adrenomedullary outflow in the rat. |
| Q35943980 | Brown adipose tissue: endocrine determinants of function and therapeutic manipulation as a novel treatment strategy for obesity |
| Q34142630 | C-3 Amido-indole cannabinoid receptor modulators |
| Q42031399 | C-terminal truncated cannabinoid receptor 1 coexpressed with G protein trimer in Sf9 cells exists in a precoupled state and shows constitutive activity |
| Q30813670 | CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice |
| Q44780794 | CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats |
| Q57319831 | CB1 Cannabinoid Receptor Antagonists |
| Q37568657 | CB1 activity in male reproduction: mammalian and nonmammalian animal models |
| Q47926400 | CB1 and CB2 Receptor Pharmacology |
| Q46431176 | CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. |
| Q28242954 | CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity |
| Q35048878 | CB1 cannabinoid receptor-mediated modulation of food intake in mice |
| Q37998561 | CB1 receptor antagonists: new discoveries leading to new perspectives |
| Q43678224 | CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain |
| Q36712228 | CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. |
| Q33293362 | CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health |
| Q24643591 | CB2 receptor-mediated migration of immune cells: it can go either way |
| Q24643895 | CB2 receptors in the brain: role in central immune function |
| Q34627188 | Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease |
| Q28298326 | Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors |
| Q33900873 | Cannabimimetic fatty acid derivatives in cancer and inflammation |
| Q43991243 | Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat. |
| Q28372132 | Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme |
| Q61640912 | Cannabinoid CB1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo |
| Q35027286 | Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries |
| Q37444808 | Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders |
| Q48569177 | Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. |
| Q44551678 | Cannabinoid CB1 receptor inhibition of mechanically evoked responses of spinal neurones in control rats, but not in rats with hindpaw inflammation |
| Q36830438 | Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions |
| Q31863511 | Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse |
| Q34098179 | Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? |
| Q48120764 | Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation |
| Q36431393 | Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug? |
| Q64263349 | Cannabinoid Receptor 1 Blockade Attenuates Obesity and Adipose Tissue Type 1 Inflammation Through miR-30e-5p Regulation of Delta-Like-4 in Macrophages and Consequently Downregulation of Th1 Cells |
| Q33980198 | Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future |
| Q28272251 | Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons |
| Q33876516 | Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. |
| Q37752096 | Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas |
| Q36891652 | Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors |
| Q37905540 | Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury |
| Q43744072 | Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters |
| Q43596412 | Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. |
| Q46569015 | Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways |
| Q90285645 | Cannabinoid ligands, receptors and enzymes: Pharmacological tools and therapeutic potential |
| Q44864213 | Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception |
| Q74506036 | Cannabinoid modulation of intestinal propulsion in mice |
| Q34214210 | Cannabinoid modulation of peripheral autonomic and sensory neurotransmission |
| Q44567447 | Cannabinoid modulation of sensitivity to time |
| Q44386037 | Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats |
| Q48151733 | Cannabinoid penetration into mouse brain as determined by ex vivo binding |
| Q35684044 | Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. |
| Q24670395 | Cannabinoid pharmacology: the first 66 years |
| Q85072476 | Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice |
| Q44454656 | Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome |
| Q77391993 | Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways |
| Q37568626 | Cannabinoid receptor CB1 antagonists state of the art and challenges. |
| Q52027564 | Cannabinoid receptor activation in CA1 pyramidal cells in adult rat hippocampus. |
| Q43760360 | Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. |
| Q43777397 | Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons |
| Q45015145 | Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways |
| Q44343504 | Cannabinoid receptor and WIN 55 212‐2‐stimulated [35S]‐GTPγS binding in the brain of mu‐, delta‐ and kappa‐opioid receptor knockout mice |
| Q44014642 | Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain |
| Q33720116 | Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. |
| Q31522100 | Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development |
| Q35593944 | Cannabinoid receptor systems: therapeutic targets for tumour intervention. |
| Q46258825 | Cannabinoid receptor-mediated inhibition of dopamine release in the retina |
| Q48506995 | Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla |
| Q28245404 | Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells |
| Q28143655 | Cannabinoid receptors and pain |
| Q34099012 | Cannabinoid receptors and the regulation of immune response |
| Q41753811 | Cannabinoid receptors and their endogenous agonist, anandamide |
| Q36044310 | Cannabinoid receptors: nomenclature and pharmacological principles |
| Q36808188 | Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats |
| Q53178937 | Cannabinoid-Induced Tetrad in Mice. |
| Q26783956 | Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis |
| Q24642509 | Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors |
| Q36953261 | Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. |
| Q92360607 | Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose |
| Q43543029 | Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit |
| Q48518726 | Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors |
| Q43594320 | Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus |
| Q92097842 | Cannabinoids and Cardiovascular System |
| Q55506613 | Cannabinoids and Reproduction: A Lasting and Intriguing History. |
| Q35046205 | Cannabinoids and neuroinflammation |
| Q34520143 | Cannabinoids and neuroprotection |
| Q48246173 | Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures |
| Q28365382 | Cannabinoids and the gastrointestinal tract |
| Q33720144 | Cannabinoids as potential new analgesics |
| Q26866298 | Cannabinoids as therapeutic agents in cancer: current status and future implications |
| Q44209120 | Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats |
| Q48382273 | Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. |
| Q36897497 | Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. |
| Q41713139 | Cannabinoids decrease the K(+) M-current in hippocampal CA1 neurons. |
| Q71706855 | Cannabinoids enhance human B-cell growth at low nanomolar concentrations |
| Q34500638 | Cannabinoids facilitate the swallowing reflex elicited by the superior laryngeal nerve stimulation in rats |
| Q37387204 | Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists |
| Q31877443 | Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens |
| Q34570764 | Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors. |
| Q28377147 | Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata |
| Q43757193 | Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages. |
| Q44026784 | Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. |
| Q44084440 | Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse |
| Q48448864 | Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. |
| Q52171870 | Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. |
| Q46879336 | Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism |
| Q30807024 | Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data |
| Q39623454 | Cannabinol and cannabidiol exert opposing effects on rat feeding patterns |
| Q34549222 | Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options |
| Q48405803 | Cannabis and endogenous cannabinoid systems. |
| Q34199483 | Cannabis and the brain |
| Q37826693 | Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation |
| Q34699888 | Cannabis, the mind and society: the hash realities |
| Q34522287 | Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia |
| Q33748898 | Cannabis: discrimination of "internal bliss"? |
| Q44138112 | Carbon-11 labeled radioligands for imaging brain cannabinoid receptors |
| Q33900883 | Cardiovascular effects of endocannabinoids--the plot thickens |
| Q57080830 | Catalyst-Free N-Arylation Using Unactivated Fluorobenzenes |
| Q38056395 | Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids |
| Q41987415 | Cellular and molecular mechanisms of drug dependence: An overview and update |
| Q42043745 | Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats |
| Q37143602 | Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. |
| Q42528535 | Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist |
| Q28242911 | Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA) |
| Q45111719 | Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats |
| Q28363051 | Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide |
| Q51807087 | Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336. |
| Q35042564 | Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves |
| Q42940476 | Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta |
| Q43668148 | Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction |
| Q35219200 | Chronic unpredictable stress enhances cocaine-conditioned place preference in type 1 cannabinoid receptor knockout mice |
| Q34636231 | Chronic Δ9‐tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross‐tolerance among cannabinoids |
| Q50622619 | College on problems of drug dependence meeting, Puerto Rico (June 1996) marijuana use and dependence. |
| Q64973158 | Comparison and Functional Genetic Analysis of Striatal Protein Expression Among Diverse Inbred Mouse Strains. |
| Q35041929 | Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine |
| Q34749408 | Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors |
| Q36890833 | Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor |
| Q37805184 | Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses |
| Q34574015 | Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors |
| Q48339729 | Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice |
| Q44580927 | Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift? |
| Q43653896 | Critical role of the endogenous cannabinoid system in mouse pup suckling and growth |
| Q54082276 | Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. |
| Q34543208 | Crystal Structure of the Human Cannabinoid Receptor CB1. |
| Q36579590 | Current and novel approaches to the drug therapy of obesity |
| Q36442442 | Deletion of Monoglyceride Lipase in Astrocytes Attenuates Lipopolysaccharide-induced Neuroinflammation |
| Q45100238 | Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism |
| Q43734938 | Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. |
| Q34170521 | Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions |
| Q43648938 | Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew |
| Q45153251 | Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice |
| Q42539438 | Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain |
| Q41002908 | Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. |
| Q42446862 | Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. |
| Q48141521 | Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol |
| Q28366135 | Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand |
| Q51773116 | Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold. |
| Q46792023 | Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists |
| Q42277604 | Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists |
| Q37395146 | Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry |
| Q34157382 | Development and consequences of cannabis dependence |
| Q34538482 | Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases. |
| Q33298869 | Developmental changes in agonist-induced retrograde signaling at parallel fiber-Purkinje cell synapses: role of calcium-induced calcium release |
| Q46886520 | Developmental decrease in short-term facilitation at Schaffer collateral synapses in hippocampus is mGluR1 sensitive. |
| Q89892013 | Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists |
| Q44264999 | Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. |
| Q28346747 | Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors |
| Q48364531 | Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. |
| Q39544994 | Dinapinones, novel inhibitors of triacylglycerol synthesis in mammalian cells, produced by Penicillium pinophilum FKI-3864. |
| Q43517979 | Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids |
| Q61479730 | Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells |
| Q34278963 | Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors |
| Q58696615 | Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis |
| Q42407000 | Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice |
| Q44914228 | Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist |
| Q34162470 | Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist |
| Q36919559 | Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats |
| Q39288073 | Dissociation of within- and between-session extinction of conditioned fear |
| Q34302379 | Diuretic effects of cannabinoids |
| Q41646203 | Dopamine activation of endogenous cannabinoid signaling in dorsal striatum |
| Q42467805 | Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse. |
| Q30359088 | Drug treatments for obesity: orlistat, sibutramine, and rimonabant. |
| Q47410278 | Dual Influence of Endocannabinoids on Long-Term Potentiation of Synaptic Transmission. |
| Q28369714 | Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor |
| Q44869208 | Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide |
| Q48062717 | Early phytocannabinoid chemistry to endocannabinoids and beyond |
| Q44028213 | Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats |
| Q77674840 | Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits |
| Q46784380 | Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats |
| Q36357902 | Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats |
| Q35028454 | Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation |
| Q43965495 | Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells |
| Q42478605 | Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity |
| Q43754879 | Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration |
| Q45114552 | Effects of SR 141716A after acute or chronic cannabinoid administration in dogs |
| Q80423729 | Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures |
| Q44865464 | Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination |
| Q27312372 | Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice |
| Q44077059 | Effects of anandamide on embryo implantation in the mouse |
| Q30442731 | Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain |
| Q46712800 | Effects of cannabinoid receptor activation on rabbit bisected vas deferens strips |
| Q43158845 | Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum |
| Q28363784 | Effects of cannabinoids on adrenaline release from adrenal medullary cells |
| Q42538098 | Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs |
| Q42491040 | Effects of castration on cannabinoid cb receptor expression and on the biological actions of cannabinoid in the parotid gland |
| Q43445796 | Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice |
| Q48428879 | Effects of endocannabinoid neurotransmission modulators on brain stimulation reward |
| Q37692352 | Effects of opioids, cannabinoids, and vanilloids on body temperature |
| Q36223797 | Effects of palmitoylethanolamide on aqueous humor outflow |
| Q42528193 | Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain |
| Q44209138 | Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia |
| Q46769723 | Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats |
| Q46316802 | Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation |
| Q44867449 | Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal |
| Q38333962 | Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice |
| Q52202168 | Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. |
| Q42076773 | Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. |
| Q33865224 | Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices |
| Q43672168 | Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. |
| Q34244610 | Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial |
| Q31059589 | Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. |
| Q45051487 | Efficient and highly regioselective synthesis of ethyl 1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylates under ultrasound irradiation |
| Q35771406 | Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge |
| Q33997873 | Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown |
| Q36108722 | Endocannabinoid control of food intake and energy balance |
| Q36711160 | Endocannabinoid mechanisms of pain modulation |
| Q35594842 | Endocannabinoid signaling directs periimplantation events |
| Q46075930 | Endocannabinoid signaling regulates spontaneous transmitter release from embryonic retinal amacrine cells |
| Q50780213 | Endocannabinoid system in frog and rodent testis: type-1 cannabinoid receptor and fatty acid amide hydrolase activity in male germ cells. |
| Q36357182 | Endocannabinoid system involvement in brain reward processes related to drug abuse |
| Q37119281 | Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment |
| Q37363621 | Endocannabinoid-mediated control of synaptic transmission |
| Q55282369 | Endocannabinoids |
| Q43658822 | Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis |
| Q34495800 | Endocannabinoids and Metabolic Disorders. |
| Q36257249 | Endocannabinoids and liver disease--review |
| Q38593136 | Endocannabinoids and the Digestive Tract and Bladder in Health and Disease |
| Q36981004 | Endocannabinoids and the control of energy homeostasis |
| Q37412217 | Endocannabinoids and the heart. |
| Q36214144 | Endocannabinoids and their implications for epilepsy |
| Q34099006 | Endocannabinoids as cardiovascular modulators |
| Q41742759 | Endocannabinoids: a new class of vasoactive substances |
| Q61479731 | Endogenous cannabinoid system as a modulator of food intake |
| Q52196139 | Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. |
| Q43818881 | Endogenous cannabinoids mediate hypotension after experimental myocardial infarction |
| Q44279121 | Endogenous cannabinoids: a new target in the treatment of obesity |
| Q56880417 | Endothelium-dependent Relaxation in Response to Ethanol in the Porcine Isolated Pulmonary Artery |
| Q46673452 | Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine |
| Q34610463 | Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors |
| Q34858094 | Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo |
| Q52141091 | Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates. |
| Q40935147 | Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system |
| Q43872448 | Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys |
| Q43064653 | Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine |
| Q48337260 | Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity |
| Q42434209 | Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation |
| Q42014580 | Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors |
| Q43812206 | Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung |
| Q33720099 | Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors |
| Q34454662 | Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. |
| Q35874137 | Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder |
| Q42003359 | Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. |
| Q28378272 | Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells |
| Q35026518 | Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist |
| Q48726145 | Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices |
| Q41904764 | Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors |
| Q35837682 | Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex |
| Q58743634 | Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations |
| Q44342705 | Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors |
| Q24309438 | Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations |
| Q90321305 | Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses |
| Q48136699 | Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide |
| Q42487420 | Facilitation and inhibition by capsaicin of cholinergic neurotransmission in the guinea-pig small intestine |
| Q36300457 | Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture |
| Q39771468 | Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X7-Evoked Glutamate Release |
| Q34004234 | Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives |
| Q47281894 | Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma |
| Q33768340 | Food for thought: endocannabinoid modulation of lipogenesis |
| Q34786818 | From cannabis to cannabinergics: new therapeutic opportunities |
| Q37370306 | From drugs to deprivation: a Bayesian framework for understanding models of psychosis |
| Q35586753 | From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? |
| Q44011406 | Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon |
| Q60155181 | Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons |
| Q35950894 | Functional genomics strategies to identify susceptibility genes and treatment targets in alcohol dependence |
| Q43662870 | Functional interaction between opioid and cannabinoid receptors in drug self-administration. |
| Q34750566 | Functions of cannabinoid receptors in the hippocampus |
| Q36341641 | Further advances in the synthesis of endocannabinoid-related ligands |
| Q35874121 | Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine |
| Q37110510 | GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats |
| Q28469322 | Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice |
| Q46947462 | Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference |
| Q43503383 | Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation |
| Q51980585 | Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. |
| Q26783258 | Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target(1,2,3) |
| Q43263219 | Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. |
| Q24595389 | Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model |
| Q43670435 | Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors |
| Q35347646 | High-fat diet-induced insulin resistance does not increase plasma anandamide levels or potentiate anandamide insulinotropic effect in isolated canine islets |
| Q41013027 | High-level expression of the human CB2 cannabinoid receptor using a baculovirus system. |
| Q33765623 | High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies |
| Q33655408 | Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol |
| Q34748762 | Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. |
| Q36434447 | How many sites of action for endocannabinoids to control energy metabolism? |
| Q34320139 | Hu 210: a potent tool for investigations of the cannabinoid system. |
| Q28190374 | Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716 |
| Q38340750 | Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. |
| Q40799260 | Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. |
| Q36452521 | Hypothalamic regulatory pathways and potential obesity treatment targets |
| Q43448744 | Hypothalamus-pituitary axis: an obligatory target for endocannabinoids to inhibit steroidogenesis in frog testis |
| Q37183687 | Hypothesis-driven medication discovery for the treatment of psychostimulant addiction |
| Q77794122 | Imidazoline binding sites and receptors in cardiovascular tissue |
| Q37244823 | Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists |
| Q47242856 | Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. |
| Q35943778 | Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature |
| Q48973251 | Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. |
| Q38612135 | In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor. |
| Q24643672 | In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models |
| Q34039683 | In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding |
| Q35028193 | In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum |
| Q74340550 | In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors |
| Q73223400 | In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments |
| Q77766471 | Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist |
| Q35042648 | Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta |
| Q46107799 | Influence of intracerebroventricular or intraperitoneal administration of cannabinoid receptor agonist (WIN 55,212-2) and inverse agonist (AM 251) on the regulation of food intake and hypothalamic serotonin levels |
| Q28143431 | Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding |
| Q59068519 | Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes |
| Q28283718 | Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction |
| Q48262695 | Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia |
| Q35874165 | Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves |
| Q35045697 | Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation |
| Q48704955 | Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. |
| Q39124297 | Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids |
| Q71378280 | Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors |
| Q44349438 | Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice |
| Q55042395 | Inhibition of salivary secretion by activation of cannabinoid receptors. |
| Q44746104 | Inhibition of voltage-sensitive sodium channels by the cannabinoid 1 receptor antagonist AM 251 in mammalian brain |
| Q36964922 | Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways |
| Q32144479 | Inhibitory effects of SR141716A on G-protein activation in rat brain |
| Q39987047 | Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression |
| Q48571061 | Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study |
| Q37444813 | Interaction of the cannabinoid and opioid systems in the modulation of nociception |
| Q35809384 | Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward |
| Q43355908 | Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. |
| Q33758351 | Interactions of Cannabinoids With Biochemical Substrates |
| Q85948164 | Interference with acute nausea and anticipatory nausea in rats by fatty acid amide hydrolase (FAAH) inhibition through a PPARα and CB1 receptor mechanism, respectively: a double dissociation |
| Q35310056 | Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide |
| Q43194095 | Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats |
| Q37778511 | Inverse Agonism at Serotonin and Cannabinoid Receptors |
| Q73011648 | Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) |
| Q45983403 | Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats. |
| Q36452404 | Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. |
| Q73879622 | Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation |
| Q37361093 | Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol |
| Q28349586 | Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide |
| Q42471169 | Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. |
| Q47963301 | Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus |
| Q36847055 | Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. |
| Q34098379 | JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects. |
| Q35045710 | Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release |
| Q42492989 | Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study |
| Q36408464 | Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential |
| Q28211969 | Leptin-regulated endocannabinoids are involved in maintaining food intake |
| Q37164807 | Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond |
| Q38031743 | Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. |
| Q90026690 | Lipokines and Thermogenesis |
| Q58126117 | Liquid Chromatographic Method with Ultraviolet Absorbance Detection for Measurement of Rimonabant in Human Plasma |
| Q33821608 | Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action |
| Q21142667 | Localization and function of the cannabinoid CB1 receptor in the anterolateral bed nucleus of the stria terminalis |
| Q31813503 | Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. |
| Q73109965 | Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281 |
| Q47726731 | Long-lasting in vivo effects of the cannabinoid CB1 antagonist AM6538. |
| Q40552011 | Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. |
| Q33373681 | Loss of cannabinoid receptor CB1 induces preterm birth |
| Q24671514 | Marijuana and cannabinoid regulation of brain reward circuits |
| Q36712200 | Marijuana dependence: not just smoke and mirrors |
| Q34986723 | Marijuana withdrawal syndrome in the animal model |
| Q74608042 | Marijuana, immunity and infection |
| Q40878576 | Marijuana. Respiratory tract effects |
| Q39635726 | Measurement of Inverse Agonism of the Cannabinoid Receptors |
| Q41683694 | Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. |
| Q33895436 | Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. |
| Q40622959 | Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis |
| Q92994067 | Membrane-associated periodic skeleton is a signaling platform for RTK transactivation in neurons |
| Q34321804 | Memory reconsolidation and extinction have distinct temporal and biochemical signatures. |
| Q34750833 | Mesolimbic dopaminergic decline after cannabinoid withdrawal |
| Q73292745 | Metabolic stimulation of mouse spleen lymphocytes by low doses of delta9-tetrahydrocannabinol |
| Q37211788 | Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing |
| Q44274441 | Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs |
| Q44303656 | Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor |
| Q43264356 | Modulation of (3)H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and beta-adrenoceptors in mouse tissues |
| Q43774276 | Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands |
| Q44532208 | Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. |
| Q37199151 | Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate |
| Q33764237 | Modulation of fear memory by dietary polyunsaturated fatty acids via cannabinoid receptors. |
| Q44100817 | Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors |
| Q41371378 | Modulation of neurotransmission by cannabinoids in the basal ganglia |
| Q36259799 | Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence |
| Q39124226 | Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum |
| Q39102188 | Molecular Pharmacology of Phytocannabinoids |
| Q24336332 | Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor |
| Q41837782 | Molecular mechanisms for the destabilization and restabilization of reactivated spatial memory in the Morris water maze |
| Q41191025 | Molecular neurobiology of the cannabinoid receptor. |
| Q34098959 | Molecular probes for the cannabinoid receptors |
| Q39141240 | Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling |
| Q33720160 | Motor actions of cannabinoids in the basal ganglia output nuclei |
| Q34373631 | Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. |
| Q31417471 | Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor |
| Q34904406 | N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors |
| Q42670939 | Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice |
| Q45711992 | Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models |
| Q48341589 | Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus |
| Q38395251 | New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds |
| Q34494301 | New insights on the role of the endocannabinoid system in the regulation of energy balance. |
| Q44468306 | New isochaetochromin, an inhibitor of triacylglycerol synthesis in mammalian cells, produced by Penicillium sp. FKI-4942: I. Taxonomy, fermentation, isolation and biological properties |
| Q37660087 | New therapeutic potential for psychoactive natural products |
| Q45006435 | Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). |
| Q38185075 | No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids |
| Q34179008 | Nonpsychotropic cannabinoid receptors regulate microglial cell migration. |
| Q36783972 | Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice |
| Q45081681 | Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide |
| Q34431882 | Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice |
| Q48179872 | Novel pyrrolocycloalkylpyrazole analogues as CB1 ligands. |
| Q37729807 | Novel selective cannabinoid CB(1) receptor antagonist MJ08 with potent in vivo bioactivity and inverse agonistic effects. |
| Q40083173 | Novel, potent THC/anandamide (hybrid) analogs. |
| Q33899423 | O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties |
| Q47808605 | Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium. |
| Q44352771 | Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats |
| Q40165311 | Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts |
| Q41229463 | Oral Administration of the Endocannabinoid Anandamide during Lactation: Effects on Hypothalamic Cannabinoid Type 1 Receptor and Food Intake in Adult Mice. |
| Q44456158 | Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice |
| Q33421146 | Pain modulation by release of the endogenous cannabinoid anandamide |
| Q40639597 | Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. |
| Q28393331 | Parabens inhibit fatty acid amide hydrolase: A potential role in paraben-enhanced 3T3-L1 adipocyte differentiation |
| Q42921222 | Peripheral Endocannabinoid System‐Mediated Actions of Rimonabant on Growth Hormone Secretion are Ghrelin‐Dependent |
| Q37669645 | Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade |
| Q38754299 | Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain |
| Q38490183 | Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control |
| Q28360193 | Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens |
| Q33893580 | Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. |
| Q39124684 | Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells |
| Q34078746 | Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation |
| Q34532228 | Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors |
| Q39791746 | Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497. |
| Q44457651 | Pharmacological effects of cannabinoids on the reference and working memory functions in mice. |
| Q44873529 | Pharmacological evaluation of aerosolized cannabinoids in mice |
| Q34125281 | Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol |
| Q34442847 | Pharmacology of cannabinoid CB1 and CB2 receptors. |
| Q28241318 | Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies |
| Q42828953 | Phosphatidylinositol transfer protein alpha regulates growth and apoptosis of NIH3T3 cells: involvement of a cannabinoid 1-like receptor |
| Q44070866 | Physiochemical and pharmacological characterization of a Delta(9)-THC aerosol generated by a metered dose inhaler |
| Q90479312 | Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol |
| Q78727774 | Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects |
| Q60474559 | Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model |
| Q34430635 | Possible mechanisms of cannabinoid-induced antinociception in the spinal cord |
| Q34103173 | Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists |
| Q90248156 | Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders |
| Q73922926 | Potentiation of anandamide hypotension by the transport inhibitor, AM404 |
| Q44344808 | Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors |
| Q95372566 | Preface |
| Q44359168 | Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. |
| Q37226537 | Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). |
| Q82183867 | Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes |
| Q36936358 | Present and future therapeutic strategies in non-alcoholic fatty liver disease |
| Q28144567 | Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons |
| Q42707987 | Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid‐mediated blockade of long‐term potentiation in the rat hippocampal slice |
| Q34397288 | Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. |
| Q40460866 | Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. |
| Q90083272 | Probing the CB1 Cannabinoid Receptor Binding Pocket with AM6538, a High-Affinity Irreversible Antagonist |
| Q37372676 | Production and physiological actions of anandamide in the vasculature of the rat kidney. |
| Q44368383 | Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice |
| Q42618328 | Purine receptor‐mediated endocannabinoid production and retrograde synaptic signalling in the cerebellar cortex |
| Q30495206 | Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis |
| Q35142614 | Quantification of Rimonabant (SR 141716A) in Monkey Plasma Using HPLC with UV Detection |
| Q33659650 | Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist. |
| Q44264992 | R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors |
| Q43812195 | Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice |
| Q38458891 | Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties |
| Q41139951 | Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis |
| Q43597369 | Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro |
| Q28363073 | Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction |
| Q33604478 | Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells |
| Q41002898 | Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells |
| Q40943005 | Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses |
| Q48198217 | Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange |
| Q48559047 | Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain |
| Q43867242 | Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids |
| Q43867297 | Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine |
| Q73704501 | Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor |
| Q46484350 | Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant |
| Q60486616 | Rimonabant |
| Q41991321 | Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells |
| Q24634816 | Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm |
| Q42794549 | Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol |
| Q81099416 | Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats |
| Q37729882 | Rimonabant inhibits TNF-α-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway |
| Q34054143 | Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2. |
| Q39650051 | Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice |
| Q37862977 | Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies |
| Q36407318 | Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors |
| Q37483205 | Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity |
| Q46900606 | Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients |
| Q43263256 | Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents |
| Q37345943 | Role of cannabinoid receptors in the control of gastrointestinal motility and perception |
| Q92613057 | Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity |
| Q53939742 | Role of non-nitric oxide non-prostaglandin endothelium-derived relaxing factor(s) in bradykinin vasodilation. |
| Q90325053 | Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention |
| Q46896371 | Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice |
| Q44865127 | Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia |
| Q43503399 | Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. |
| Q60155183 | Role of the superior colliculus in the motor effects of cannabinoids and dopamine |
| Q47628019 | SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice |
| Q44176704 | SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study |
| Q42445979 | SR141716A is an inverse agonist at the human cannabinoid CB1 receptor |
| Q51375099 | Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. |
| Q47987506 | Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice |
| Q28346418 | Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues |
| Q99407998 | Sex and Strain Variation in Initial Sensitivity and Rapid Tolerance to Δ9-Tetrahydrocannabinol |
| Q28363046 | Signal transduction pathways involved in kinin B(2) receptor-mediated vasodilation in the rat isolated perfused kidney |
| Q24309197 | Similar in vitro pharmacology of human cannabinoid CB1 receptor variants expressed in CHO cells |
| Q37210189 | Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users |
| Q38115668 | Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system? |
| Q35035850 | Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives |
| Q43562046 | Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. |
| Q28374277 | Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60 |
| Q42713279 | Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays |
| Q89539285 | Structural Optimization of the Diarylurea PSNCBAM-1, an Allosteric Modulator of Cannabinoid Receptor 1 |
| Q34152254 | Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. |
| Q41214405 | Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. |
| Q57469299 | Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists |
| Q28346456 | Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens |
| Q24555807 | Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase |
| Q34374106 | Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats |
| Q36358712 | Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate |
| Q34320289 | Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans |
| Q44867023 | Synergistic interactions of endogenous opioids and cannabinoid systems |
| Q53012810 | Synthesis and 11C-Radiolabelling of 2-Carboranyl Benzothiazoles. |
| Q37074591 | Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazoles |
| Q41855701 | Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice |
| Q34264537 | Synthesis and testing of novel phenyl substituted side-Chain analogues of classical cannabinoids |
| Q36984451 | Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging |
| Q41428934 | Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice |
| Q47920779 | THC Treatment Alters Glutamate Receptor Gene Expression in Human Stem Cell-Derived Neurons |
| Q28271125 | TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat |
| Q33960904 | Tetrahydrocannabinol and endocannabinoids in feeding and appetite |
| Q34360054 | Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus |
| Q38319183 | The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors |
| Q35045001 | The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions |
| Q64070160 | The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q38659944 | The Endocannabinoid Signaling System in the CNS: A Primer. |
| Q38974429 | The Role of Cannabinoid Receptors in the Descending Modulation of Pain |
| Q35028088 | The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery |
| Q40817229 | The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism |
| Q83898066 | The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids |
| Q36961414 | The cannabinoid CB(1) receptor antagonist CE prolongs spatial memory duration in a rat delayed radial arm maze memory task |
| Q43723090 | The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus |
| Q52047485 | The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. |
| Q43791910 | The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. |
| Q35029262 | The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. |
| Q36977773 | The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence |
| Q41155236 | The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. |
| Q48482096 | The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons |
| Q36492788 | The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. |
| Q42607871 | The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats |
| Q34159121 | The cannabinoid receptors. |
| Q34040002 | The cannabinoid system and cytokine network |
| Q35213813 | The cannabinoid system and immune modulation |
| Q36655240 | The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide |
| Q84616297 | The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice |
| Q44867675 | The discovery of endogenous cannabinoids |
| Q82448643 | The discovery of novel indole-2-carboxamides as cannabinoid CB1 receptor antagonists |
| Q24643876 | The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin |
| Q44494968 | The effect of cannabinoid receptor antagonism with SR141716A on antinociception induced by cocaine and the NMDA receptor antagonist, MK-801. |
| Q48094949 | The effects of beta-arrestin1 deletion on acute cannabinoid activity, brain cannabinoid receptors and tolerance to cannabinoids in mice. |
| Q28137626 | The effects of cannabinoids on the brain |
| Q47567233 | The effects of fasting duration on gastric emptying in man, an exploration of the role of the endocannabinoid system and inter-individual responsiveness |
| Q46213429 | The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. |
| Q33790150 | The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels |
| Q36977769 | The endocannabinoid system and extinction learning |
| Q35876026 | The endocannabinoid system and its therapeutic exploitation |
| Q34626755 | The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. |
| Q33934278 | The endocannabinoid system as a target for therapeutic drugs. |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q36741861 | The endocannabinoid system in brain reward processes |
| Q36394348 | The endocannabinoid system: a new approach to control cardiovascular disease |
| Q36701773 | The endocannabinoid system: body weight and metabolic regulation |
| Q35954057 | The endocannabinoid system: physiology and pharmacology. |
| Q36926051 | The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys |
| Q34066911 | The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. |
| Q41048004 | The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines |
| Q45753821 | The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway |
| Q28280255 | The endogenous cannabinoid system and drug addiction: 20 years after the discovery of the CB1 receptor |
| Q34786832 | The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. |
| Q44085607 | The endogenous cannabinoid system controls extinction of aversive memories |
| Q54363472 | The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. |
| Q24522320 | The neurobiology and evolution of cannabinoid signalling |
| Q28645703 | The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling |
| Q43619986 | The pharmacological activity of inhalation exposure to marijuana smoke in mice |
| Q34990771 | The psychiatric side-effects of rimonabant |
| Q34472972 | The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats |
| Q28085261 | The role of cannabinoids in adult neurogenesis |
| Q34268475 | The role of cannabinoids in neurodegenerative diseases |
| Q36434442 | The role of the endocannabinoid system in the control of energy homeostasis. |
| Q37913717 | The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. |
| Q45104866 | The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats |
| Q37402927 | The therapeutic potential of novel cannabinoid receptors |
| Q26996134 | The thrifty lipids: endocannabinoids and the neural control of energy conservation |
| Q71769876 | The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period |
| Q36187065 | Therapeutic potential of cannabinoid receptor agonists as analgesic agents |
| Q33964721 | Therapeutic potential of cannabinoids in CNS disease |
| Q44874932 | Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice |
| Q48683075 | Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics |
| Q44551331 | Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons |
| Q37086961 | Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action |
| Q60228969 | Toward the design of cannabinoid CB1 receptor inverse agonists and neutral antagonists |
| Q33906007 | Towards cannabinoid drugs--revisited. |
| Q46848662 | Transdermal delivery of the synthetic cannabinoid WIN 55,212-2: in vitro/in vivo correlation |
| Q44241696 | Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors. |
| Q44334367 | Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. |
| Q33302186 | Understanding cannabinoid psychoactivity with mouse genetic models |
| Q86924782 | Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke |
| Q37556938 | Updates in reproduction coming from the endocannabinoid system. |
| Q38248001 | Using the endocannabinoid system as a neuroprotective strategy in perinatal hypoxic-ischemic brain injury |
| Q38756777 | Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection |
| Q41105693 | Vascular Dysfunction in a Transgenic Model of Alzheimer's Disease: Effects of CB1R and CB2R Cannabinoid Agonists |
| Q36358729 | Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat. |
| Q79964935 | Vasorelaxant effect of Win 55,212-2 in rat aorta: new mechanisms involved |
| Q77291037 | Watching the pot boil |
| Q34411768 | Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? |
| Q74501955 | [The pharmacology of cannabinoid derivatives: are there applications to treatment of pain?] |
| Q42439738 | delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons. |
| Q44345904 | delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors |
| Q60948556 | ∆-Tetrahydrocannabinol, a major marijuana component, enhances the anesthetic effect of pentobarbital through the CB receptor |
Search more.